Louisiana State Employees Retirement System Purchases 100 Shares of Repligen Corporation $RGEN

Louisiana State Employees Retirement System grew its position in Repligen Corporation (NASDAQ:RGEN) by 0.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,700 shares of the biotechnology company’s stock after acquiring an additional 100 shares during the period. Louisiana State Employees Retirement System’s holdings in Repligen were worth $1,828,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Slow Capital Inc. raised its stake in shares of Repligen by 8.2% in the second quarter. Slow Capital Inc. now owns 35,565 shares of the biotechnology company’s stock valued at $4,424,000 after acquiring an additional 2,688 shares during the last quarter. KLP Kapitalforvaltning AS raised its stake in shares of Repligen by 5.8% in the second quarter. KLP Kapitalforvaltning AS now owns 11,000 shares of the biotechnology company’s stock valued at $1,368,000 after acquiring an additional 600 shares during the last quarter. 111 Capital bought a new position in shares of Repligen in the second quarter valued at approximately $358,000. Hilltop National Bank bought a new position in shares of Repligen in the second quarter valued at approximately $147,000. Finally, Congress Asset Management Co. raised its stake in shares of Repligen by 18.0% in the second quarter. Congress Asset Management Co. now owns 152,450 shares of the biotechnology company’s stock valued at $18,962,000 after acquiring an additional 23,231 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling

In other news, Director Martin D. Madaus purchased 1,800 shares of the firm’s stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $112.13 per share, with a total value of $201,834.00. Following the acquisition, the director directly owned 1,800 shares of the company’s stock, valued at approximately $201,834. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Wall Street Zen raised shares of Repligen from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reissued a “sell (d)” rating on shares of Repligen in a report on Wednesday. Barclays raised their price target on shares of Repligen from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Jefferies Financial Group lowered their price target on shares of Repligen from $145.00 to $135.00 and set a “hold” rating for the company in a report on Friday, September 12th. Finally, Wells Fargo & Company lowered their price target on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and a consensus price target of $169.62.

Repligen Price Performance

RGEN opened at $145.24 on Friday. The company has a fifty day moving average price of $125.12 and a two-hundred day moving average price of $125.62. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $182.52. The firm has a market capitalization of $8.17 billion, a PE ratio of -580.94, a P/E/G ratio of 2.68 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same period in the prior year, the firm posted $0.40 EPS. Repligen’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.